Trial achieved biological proof-of-concept, dose discovery and biomarker improvement

San Diego, California–(Newsfile Corp. – November 4, 2025) – Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) (“Thiogenesis” or the “Company”) a clinical-stage biotechnology company developing sulfur-based therapeutics for pediatric diseases, predominantly those involving mitochondrial dysfunction, today announced interim results from its Phase 2 clinical trial of TTI-0102 for Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes or MELAS, which is being conducted at Radboud University in the Netherlands and CHU Angers in France. The Company also provided updates regarding its progress and planning related to its Leigh syndrome spectrum and nephropathic cystinosis clinical progr

See Full Page